NASDAQ:DNTH Dianthus Therapeutics Q4 2024 Earnings Report $86.84 +1.37 (+1.60%) Closing price 03:58 PM EasternExtended Trading$86.72 -0.12 (-0.14%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dianthus Therapeutics EPS ResultsActual EPS-$0.81Consensus EPS -$0.85Beat/MissBeat by +$0.04One Year Ago EPSN/ADianthus Therapeutics Revenue ResultsActual Revenue$1.33 millionExpected Revenue$1.40 millionBeat/MissMissed by -$70.00 thousandYoY Revenue GrowthN/ADianthus Therapeutics Announcement DetailsQuarterQ4 2024Date3/11/2025TimeAfter Market ClosesConference Call DateTuesday, March 11, 2025Conference Call Time4:00PM ETUpcoming EarningsDianthus Therapeutics' Q2 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Dianthus Therapeutics Earnings HeadlinesLBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and DermatomyositisMay 5 at 10:57 PM | globenewswire.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial ResultsMay 5 at 4:01 PM | globenewswire.comBatten down the hatches – Project Tengu is comingStarting June 16, This AI Lab Could Take Off Dramatically Time magazine recently named this lab "the most disruptive company in the world." It's not SpaceX or OpenAI. In fact, its annualized revenues have already surpassed both of these firms. And this 60-year Wall Street legend believes it's gearing up for a watershed product launch that could send its sales soaring even higher starting June 16.May 8 at 1:00 AM | Chaikin Analytics (Ad)Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comAssessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst OptimismApril 27, 2026 | finance.yahoo.comDianthus Therapeutics Inc (DNTH): FDA Makes Trials EasierApril 23, 2026 | insidermonkey.comSee More Dianthus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email. Email Address About Dianthus TherapeuticsDianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.View Dianthus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusAppLovin Pops After Earnings With Growth Catalysts in SightDutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckThe AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% Rally Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
